RAD51 Expression as a Biomarker to Predict Efficacy of Platinum-Based Chemotherapy and PD-L1 Blockade for Muscle-Invasive Bladder Cancer.
Li B, Jin K, Liu Z, Su X, Xu Z, Liu G, Xu J, Chang Y, Wang Y, Zhu Y, Xu L, Wang Z, Liu H, Zhang W. RAD51 Expression as a Biomarker to Predict Efficacy of Platinum-Based Chemotherapy and PD-L1 Blockade for Muscle-Invasive Bladder Cancer. Journal Of Immunotherapy 2024 PMID: 38800996, DOI: 10.1097/cji.0000000000000525.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerPD-L1 blockadePlatinum-based chemotherapyPD-L1Zhongshan HospitalBladder cancerProgrammed cell death ligand 1Muscle-invasive bladder cancer patientsResponse to platinum-based chemotherapyEfficacy of platinum-based chemotherapyCell death ligand 1DNA damage repairPD-L1 inhibitorsDeath-ligand 1Tumor immune contexturePredictive efficacyGenomic instabilityIMvigor210 cohortImmune contextureChemotherapeutic responseTherapeutic responseClinical benefitRetrospective studyClinical valueTherapeutic guidanceIntegration of CD4+ T cells and molecular subtype predicts benefit from PD‐L1 blockade in muscle‐invasive bladder cancer
Liu G, Jin K, Liu Z, Su X, Xu Z, Li B, Xu J, Liu H, Chang Y, Zhu Y, Xu L, Wang Z, Wang Y, Zhang W. Integration of CD4+ T cells and molecular subtype predicts benefit from PD‐L1 blockade in muscle‐invasive bladder cancer. Cancer Science 2024, 115: 1306-1316. PMID: 38402640, PMCID: PMC11007017, DOI: 10.1111/cas.16119.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerImmune checkpoint blockadeCombination of immune checkpoint blockadeCD4<sup>+</sup> T cellsFibroblast growth factor receptor 3T cellsZhongshan HospitalMolecular subtypesBladder cancerMuscle-invasive bladder cancer patientsResponses to FGFR inhibitorsCD4+ T cellsPD-L1 blockadeImmune suppressive microenvironmentTransforming growth factor-bGrowth factor BIMvigor210 cohortCheckpoint blockadePD-L1Clinical responseSuppressive microenvironmentImmune microenvironmentImmunotherapeutic responseChemotherapeutic responseClinical outcomesPOLQ identifies a better response subset to immunotherapy in muscle‐invasive bladder cancer with high PD‐L1
Liu G, Jin K, Liu Z, Su X, Xu Z, Li B, Xu J, Chang Y, Wang Y, Zhu Y, Xu L, Xu J, Wang Z, Liu H, Zhang W. POLQ identifies a better response subset to immunotherapy in muscle‐invasive bladder cancer with high PD‐L1. Cancer Medicine 2024, 13: e6962. PMID: 38457207, PMCID: PMC10922026, DOI: 10.1002/cam4.6962.Peer-Reviewed Original ResearchConceptsMuscle-invasive bladder cancerProgrammed cell death ligand 1Immune checkpoint blockadeTumor mutational burdenImmune microenvironmentZhongshan HospitalBladder cancerInfiltration of immune effector cellsEfficacy of immune checkpoint blockadePOLQ expressionCell death ligand 1High tumor mutational burdenChromosomal instabilityActive tumor immune microenvironmentAntitumor immune microenvironmentDeath-ligand 1Efficacy of immunotherapyPlatinum-based chemotherapyTumor immune microenvironmentSensitivity to chemotherapyImmune effector cellsProduction of neoantigensIMvigor210 cohortCheckpoint blockadePD-L1